STUDresearch · Non-peptide

Orforglipron

Also known as

LY3502970 · Foundayo (branded oral orforglipron — weight indication discussion) · Oral non-peptide GLP-1 agonist · Oral small-molecule GLP-1 RA · Lilly oral GLP-1 (discussion shorthand) · Orforglipron pill (forum shorthand) · Orf / orfor (forum shorthand)

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗

Non-peptide Some talk Systemic Oral Metabolic / GLP-1 class

Systemic oral GLP-1 small molecule, not a peptide; appetite, satiety, gastric-emptying and glucose effects extend beyond the gut.

What people say People compare Foundayo's daily GLP-1 pill convenience with injections and oral semaglutide's fasting rules. Appetite and food-noise reports vary; the pill format does not remove GI effects or make it equivalent to tirzepatide. Doses people talk about

Early tablet-use discussion0.8 mg once daily

Preserved early logs distinguish hunger from quieter food thoughts. The separately linked day-one poster withheld the dose, so that account cannot be assigned to 0.8 mg.

Commercial tablet ceiling17.2 mg once daily

The usual labeled maximum, not a target for every user. Interactions and tolerability can require a different clinical regimen.

Historical ATTAIN-1 capsules6 / 12 / 36 mg once daily

Separate trial arms over ~72 weeks. Sponsor research maps them to 5.5 / 9 / 17.2 mg tablets; this does not validate a conversion for gray-market products.

The first row reflects an amount in the preserved early-use discussion. The full label sequence and historical trials remain in the notes; none is a step-up recommendation.

Half-life & effect duration

Half-life in the body: Foundayo labelAbout 29–49 hours
Early single-dose studyAbout 24.6–35.3 hours
Early repeated-dose studyAbout 48.1–67.5 hours
Felt duration people report: One day-one accountFullness within hours, earlier meal stopping and fewer food thoughts
Nausea in that accountNone reported that day

Timing context & sources

How it may feel One day-one poster described earlier fullness within hours and quieter food thoughts without nausea, but withheld the dose. Other preserved reports describe persistent hunger, GI upset or fatigue; scale changes and appetite do not share one clock.

Cycles people discuss Discussion is about sustained weight management and maintenance, not a 4–6-week bodybuilding cycle. Monthly label steps, longer trial follow-up and switching from injections are distinct contexts; off-periods are not standardized. Timing Tablets are taken once daily at a consistent time, with or without food. Morning and bedtime routines are both reported, mainly around habit and GI comfort; neither is established as universally better. Stacks Most comparisons concern switching, not combining incretin drugs. Protein, resistance training, fiber and GI supports appear as adjuncts; the label cautions against another GLP-1 receptor agonist alongside Foundayo. Access talk Not a peptide, not a pen: Small-molecule GLP-1 agonist. No SNAC empty-stomach ritual, no reconstitution math, no “compounded orf” shortage story like sema/tirz. Labs people mention A1c / glucose: ACHIEVE diabetes programs and ATTAIN-1 prediabetes secondaries are why people still watch sugar even on a weight pill. Watch for GI class effects (most common): Nausea, vomiting, diarrhea, constipation, dyspepsia, decreased appetite — mostly mild–moderate, peak at start and each titration step.

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

Approximately 29–49 hours after oral dosing in the current Foundayo label.

Human PK section: peak concentration at 4–8 hours and steady exposure after roughly one week; most data use the corresponding investigational formulation, not every tablet product.

Plasma elimination is not felt appetite duration. Historical Phase 1 values differ by dose/cohort, and gray-market products cannot inherit the label estimate.

Foundayo prescribing information, July 2026 (opens in a new tab)Current label OFG-0002-USPI-20260729: §§2.1/2.3 dosing and missed doses; §6.1 formulation note; §§12.2–12.3 absorption/food/elimination; boxed warning and §13.1 rodent specificity. Actual label text read.Product-specific human PK; most values come from a corresponding investigational formulation. IV distribution measurements do not make Foundayo an injectable product.

Felt duration people report

Fullness within hours in one day-one account; no dependable duration established.

After an 8 am dose, the author described earlier meal stopping, fewer food thoughts and no nausea. The same author declined to state the amount; visible later questions did not supply an outcome update.

One uncontrolled account with unverified product/formulation. First-day observations cannot predict multi-week appetite response or clearance.

Testing the new orforglipron pill — day 1 log (opens in a new tab)Conscious-Act5378 OP: 8 am oral dose, fullness within hours, less snacking through dinner, no nausea/headache. Same-author reply to Extension-Sleep3131 explicitly withholds dosing; later update questions were also inspected.Amount and product identity not verified or disclosed; no later outcome was visible in the accessed reply chain. Do not assign the report to a Foundayo strength or treat its day-3 expectation as an observed result.

Other context in this card

ADA 2026 poster 1666-P: ATTAIN-1 formulation mapping (opens in a new tab)Accessible poster text, Background and trial figure notes: 6/12/36 mg capsules expressed as 5.5/9/17.2 mg tablets, respectively; 72-week treatment-regimen-estimand weight means. Actual full text and footnotes read.Sponsor-funded post-hoc presentation; mapping applies to specified investigational capsules and commercial tablets, not arbitrary formulations or other drugs.

What people say 20

Appetite / food noise: Class GLP-1 satiety and earlier meal stop — dominant user-facing effect, not stimulant energy. forum
Vs injectable ceiling talk: Mean % loss trails high-dose tirzepatide / retatrutide obesity curves — forums frame orf as “oral convenience tier,” not “max % loss king.” forum
Day-1 “halfway through sushi” logs: r/FoundayoUS and r/antidietglp1 2026 first-week posts describe food still sounding good until mid-plate interest drops — GLP satiety, not a stimulant kick. forumanecdote
Needle-averse / cash-pay driver: 2026 users pick the pill when Zepbound self-pay is out of range or they will not inject — convenience and price talk, not a claim it matches 15 mg tirz. forum
Stop → regain class talk: 2026 oral-GLP launch chatter cites the same “most of the loss comes back in a year off drug” meta-story as the injectables. Persistence, not week-20 scripts, is the argument. forumtrial
Phase 2 obesity (36 wk, no T2D): Mean weight −9.4% (12 mg) to −14.7% (45 mg) vs −2.3% placebo; baseline mean ~108.7 kg / BMI ~37.9. trial
Phase 2 mid-point (26 wk): Dose-dependent means −8.6% to −12.6% vs −2.0% placebo. trial
Phase 2 responders (≥10% at wk 36): ~46% (12 mg), ~62% (24 mg), ~75% (36 mg), ~69% (45 mg) vs ~9% placebo; ≥5% responders ~72–92% vs ~24% placebo. trial
ATTAIN-1 Phase 3 obesity (72 wk, n=3,127, no diabetes): Treatment-regimen estimand means −7.5% (6 mg), −8.4% (12 mg), −11.2% (36 mg) vs −2.1% placebo. trial
ATTAIN-1 efficacy estimand (on-treatment style): 36 mg ~−12.4% (~27.3 lb / ~12.4 kg) vs ~−0.9% (~2.2 lb) placebo. trial
ATTAIN-1 high-dose responders (36 mg, treatment-regimen): ~54.6% ≥10%, ~36.0% ≥15%, ~18.4% ≥20% vs ~12.9% / ~5.9% / ~2.8% placebo; efficacy-estimand secondary often quoted ~59.6% ≥10% and ~39.6% ≥15%. trial
ATTAIN-2 (obesity + T2D, 72 wk): 36 mg mean ~−10.5% (~22.9 lb) vs ~−2.2% (~5.1 lb) placebo (efficacy estimand) — less mean % loss than non-diabetes obesity cohorts, class-typical pattern. trial
ACHIEVE-1-type T2D (40 wk): A1C cut ~1.3–1.6% from ~8.0% baseline across 3/12/36 mg arms; highest-dose weight ~−7.9% (~16 lb) with plateau not yet fully reached at study end in some summaries. trial
ACHIEVE-3 vs oral semaglutide (T2D head-to-head talk): Orforglipron A1C roughly −1.9% to −2.2% (12–36 mg trial arms) vs oral sema ~−1.1% to −1.4% (7–14 mg); weight ~−8.2% orf 36 mg vs ~−5.3% oral sema 14 mg in reported comparisons. trial
Cardiometabolic secondaries: Waist, systolic BP, triglycerides, non-HDL cholesterol improved vs placebo in ATTAIN-1; highest-dose exploratory hsCRP ~−47.7%. trial
Dosing convenience: Once daily any time; no food/water restrictions like oral peptide semaglutide — major real-world differentiator in discussion. trial
Maintenance after injectables (ATTAIN-MAINTAIN): Switch from Wegovy or Zepbound to oral orforglipron held most prior loss vs placebo over 52 weeks (sema switch ~0.9 kg average difference; tirz switch ~5.0 kg difference on efficacy estimand; % of prior reduction maintained ~79% after sema / ~75% after tirz vs much lower on placebo). trial
On-drug hold: Continued daily therapy is the evidence model for keeping loss; stop → class regain/appetite rebound risk. trial
Absolute pounds framing (ATTAIN-1 press): ~17.6 lb (6 mg), ~20.7 lb (12 mg), ~27.3 lb (36 mg) efficacy-estimand averages — individuals vary widely. trial
Prediabetes signal (ATTAIN-1): Among ~1,127 with prediabetes at baseline, up to ~91% on orforglipron reached near-normal glucose vs ~42% placebo at 72 weeks (sponsor secondary framing). trial

Doses people talk about 19

Not interchangeable mg: Orforglipron mg ≠ semaglutide, tirzepatide, retatrutide, compounded peptide, or gray “oral GLP-1” powder mg. forum
Gray-market uncertainty: Non-trial oral “GLP-1” authenticity, purity, and dose accuracy remain open structural risks. forum
“Stay low as long as it works”: Community/clinic talk often holds the lowest effective maintenance step rather than auto-climbing to max if appetite is already controlled. forum
Missed dose / restart: Community/class discussions describe GI sensitivity returning after gaps and restarting at a lower step rather than a prior high dose. This is not a rule for every missed pill: the current Foundayo label specifies lower-dose re-escalation after 7 or more consecutive missed doses and warns against doubling a missed dose. forum
Hold the step: 2026 first-use culture copies the label’s ≥30-day holds. Phase 2 fast weekly climbs are the GI-horror story people cite for not rushing. trialforum
Commercial ↔ trial formulation map: The sponsor's ADA 2026 ATTAIN-1 poster maps 6 / 12 / 36 mg investigational capsules to 5.5 / 9 / 17.2 mg tablets, respectively, alongside −7.5% / −8.4% / −11.2% treatment-regimen-estimand weight means. These were previously presented in press/education discussion as approximate mid/high-step comparisons. The explicit product mapping is not a general conversion for gray-market formulations. trial
Commercial mg ≠ trial capsule mg: Forums still mix 36 mg ATTAIN headlines with 17.2 mg Foundayo tablets. Bioequivalence talk is 17.2 mg tablet ≈ 36 mg trial capsule — do not treat the numbers as 1:1. trial
Framing: Trial arms, labeled Foundayo schedule, and community discussion only — research/educational, not advice or a use protocol. forum
Labeled Foundayo ladder (weight discussion, ≥30 days per step): 0.8 mg → 2.5 mg → 5.5 mg → then 9 mg → 14.5 mg → 17.2 mg once daily based on response/tolerability. trial
Labeled max: 17.2 mg once daily is the usual commercial ceiling discussed for Foundayo tablets. trial
Trial ↔ tablet bioequivalence (sponsor talk): 17.2 mg Foundayo tablet ≈ exposure of the 36 mg capsule arm used in pivotal obesity trials — raw mg numbers are not 1:1 across formulations. trial
Phase 2 obesity arms: 12, 24, 36, 45 mg once daily for 36 weeks (historical trial capsules; 45 mg not a standard Phase 3 obesity maintenance arm). trial
Phase 3 obesity ATTAIN-1 arms: 6, 12, 36 mg once daily over ~72 weeks after stepped titration. trial
Phase 3 ATTAIN-2 (obesity + T2D) arms: Same 6 / 12 / 36 mg maintenance targets after 1 mg start and 4-week steps. trial
Diabetes ACHIEVE-type arms: Common reported maintenance arms 3, 12, 36 mg once daily (plus later commercial-strength mappings in Foundayo T2D filings talk). trial
Phase 3 titration pattern (ATTAIN / ACHIEVE): Start ~1 mg once daily; step at ~4-week intervals — e.g. 6 mg path via 1→3→6; 12 mg via 1→3→6→12; 36 mg via 1→3→6→12→24→36. Dose reduction only for GI if other mitigations failed in protocol language. trial
Phase 2 escalation note: Up to ~16 weeks of escalation depending on cohort; some arms started 2–3 mg with faster weekly steps — rapid escalation linked to more GI in discussion of the 24 mg cohort. trial
Schedule / food: Once daily, any time of day; no strict pre-meal fasting or limited-water rules like oral peptide semaglutide. trial
Swallow whole: Commercial tablet guidance discusses swallow whole — do not break/crush/chew (label-style handling). trial

How it may feel 10

Days 1–7: Mild GI (nausea, early fullness, appetite dulling) or little scale change at starter steps; not a stimulant “kick.” In one actual day-one account, the poster described fullness within hours, quieter food thoughts and no nausea after an 8 am dose; when asked, the same author deliberately withheld the amount and did not provide a timed outcome update in the accessed replies. forumanecdote
Energy / under-fuel: Fatigue and “drag” when total intake collapses without protein/electrolytes — common class talk, not unique to orf. forum
If flat mid-titration: Check calories/protein, adherence, other meds, and expectations vs dual/triple injectables before “max dose panic.” forum
Bedtime camp (2026): People who hate empty-stomach morning nausea (Rybelsus-style) take Foundayo at night so early GI sleeps. First nights can include odd dreams; that talk fades in the same threads. forumanecdote
Lunch-time still hungry, brain quieter: Early 0.8 mg logs split stomach growl vs “less excited to eat.” Not a 15 mg tirz mute. forum
Weeks 1–4 (titration start): GI peaks cluster at initiation and each step-up; “go slow / hold the step” culture matches trial escalation logic. trial
Weeks 4–12: Clearer appetite drop and earlier meal stop for responders before largest multi-month weight deltas. trial
Months 3–6 (Phase 2 reference): Wk 26 means ~−8.6% to −12.6% vs ~−2.0% placebo — mid-program progress check, not final ceiling. trial
Months 6–18 (ATTAIN-1): 72-week curves are the main long-horizon obesity reference; loss continues well past the early honeymoon for many trial participants. trial
GI curve: Nausea, constipation, diarrhea, vomiting, dyspepsia — mostly mild–moderate, front-loaded during escalation, often eases after weeks at a stable dose. trial

Around the dose 7

Clock: Once daily, any time. Consistency beats a magic hour. Bedtime is the 2026 nausea-sleep camp; morning is fine if GI is quiet. forum
Food: No Rybelsus empty-stomach / 4-oz-water / 30-minute wait. The label permits use with or without food. Greasy dose-day meals are still a nausea story. trialforum
Training: Same protein + lifting pairing as other GLPs. The pill quiets food; it does not chew. forum
Alcohol / dinner: No fasting window to protect, but delayed emptying still makes a wine-and-fried-food night a reflux post. forum
After a step-up: Smaller plates, slower eating, water. GI clusters at each ≥30-day climb, then often eases. trial
Don’t stack another GLP-1: Label talk is not to combine with other GLP-1 receptor agonists. Switch, don’t dual. trial
Oral-med timing: Delayed emptying can change absorption of some pills (including oral contraceptives in class labeling culture). trial

Cycles people discuss 7

Maintenance philosophy: Lowest dose that holds appetite/weight with tolerable GI is common long-game discussion. forum
Model: Multi-month to chronic continuous once-daily therapy — not a short 4–6 week bodybuilding cut cycle. trial
On-ramp length: Full ladder to high maintenance is many weeks of ≥4-week (trial) or ≥30-day (label) steps — GI drives holds more than calendar rushing. trial
Evidence blocks: Phase 2 obesity ~36 wk; ATTAIN obesity ~72 wk; ACHIEVE diabetes ~40–52+ wk windows; ATTAIN-MAINTAIN maintenance 52 wk after prior injectables. trial
Off periods: Not standardized; class regain after stop is well documented for incretins generally — orf is not “one-and-done.” trial
Stop / switch / restart: Community re-titration talk after gaps is distinct from the Foundayo label's threshold of 7 or more consecutive missed doses. Injectable ↔ oral switches remain formal research themes (ATTAIN-MAINTAIN), not DIY dual stacking. trial
Time-to-goal: Individual; trial means keep moving for many months — not a 2-week scale miracle. trial

Timing 13

Effect vs plasma clock: Satiety/food-noise effects are not limited to Tmax hour — users report all-day appetite blunt on stable daily dosing. forum
After stop: Levels fall over several days (multi-half-life washout); appetite/weight benefits are not permanent without ongoing therapy or lifestyle hold. forum
Single-dose t½ (Phase 1 healthy): ~24.6–35.3 hr after ~0.3–6 mg oral. trial
Steady-state t½ (Day 28 MAD): ~48.1–67.5 hr after 28 days at ~2–24 mg daily — often summarized as ~25–68 hr overall range. trial
Current oral label context: The Foundayo label reports an oral elimination half-life of ~29–49 hours. Its PK section uses corresponding investigational-formulation data except for the food study; early Phase 1 dose/cohort-specific values and current tablet labeling are not one pooled estimate. trial
Tmax: Peak concentration often ~4–12 hr post-dose (median frequently ~4–8 hr across studies). trial
Accumulation: Once-daily dosing accumulation ratios often ~1.5–1.6× vs single dose in Phase 1 summaries. trial
Dose proportionality: PK approximately dose-proportional for Cmax/AUC in early studies. trial
Oral bioavailability — contexts differ: Older preclinical/early-summary discussion quotes ~20–40%, compared with ~0.4–1% for human oral peptide semaglutide. Those are not an established current Foundayo human estimate or a cross-product dose conversion. The current label reports 77% absolute bioavailability after a 0.8 mg oral dose. trial
Food effect: Older summaries described a modest Cmax decrease (~20%). The current label's investigational 37.5 mg tablet food study reports Cmax −26% and AUC −19%, with unchanged Tmax/half-life; labeled use is with or without food. These formulation-specific findings do not create a semaglutide-style fasting rule. trial
Once-daily schedule: The multi-day half-life at steady state is discussed alongside once-daily use, not as weekly peptide-depot logic or BID danuglipron-style dosing. The schedule comes from the product's tested/labeled regimen; residence alone does not establish a personal dosing interval. trial
Gastric emptying: The label describes a delay greatest after the first dose that diminishes over time. Satiety, nausea and oral-drug absorption cautions are related clinical concerns, not proof that a multi-day plasma half-life fixes the duration of gastric slowing or appetite effects. trial
Heart rate: ATTAIN-1 mean pulse increase ~+4.3 to +5.3 bpm on orforglipron vs ~+0.8 bpm placebo — class-consistent modest rise. trial

Stacks 10

Not dual full-dose GLP-1 stacked: Formal programs study orforglipron as oral monotherapy — concurrent full-dose sema/tirz/reta co-use is generally discouraged (GI load, unknown additive risk). forum
Community adjuncts: High protein, resistance training, electrolytes, fiber timing, and GI supports (ginger, smaller low-fat meals) for lean-mass and tolerability. forum
Comparisons, not combos: Constant forum ranking vs semaglutide, tirzepatide, retatrutide, Rybelsus/oral Wegovy, danuglipron — usually switch logic. forum
Other research peptides: Occasional BPC-157 (gut), GHS, AOD/frag talk alongside any GLP-1 — outcomes heavily confounded. forum
Orf + tirz in the same week: Community caution focuses on overlapping incretin pathways and stacked GI burden; these concerns are not a validated co-use protocol. forum
vs oral Wegovy / Rybelsus: Comparison shopping is food-rule + indication (Foundayo is the weight pill without the SNAC ritual). Not a DIY combo. forum
Lifestyle co-intervention: Reduced-calorie diet + physical activity is the evidence-linked backbone in ATTAIN/ACHIEVE designs. trial
Injectable → oral sequence: ATTAIN-MAINTAIN models switch from Wegovy or Zepbound to oral orf for maintenance — sequenced, not stacked. trial
Metformin / other T2D meds: Clinician territory in diabetes programs; hypoglycemia risk rises mainly with insulin/secretagogues (class). trial
Injectable → pill maintenance: ATTAIN-MAINTAIN is the 2026 switch headline (Wegovy or Zepbound → oral orf held most prior loss vs placebo). Sequenced, not stacked. trial

Access talk 6

Not a peptide, not a pen: Small-molecule GLP-1 agonist. No SNAC empty-stomach ritual, no reconstitution math, no “compounded orf” shortage story like sema/tirz. trialforum
Cash / coupon talk: 2026 launch coverage cited roughly $149–$349/month self-pay by dose and ~$25/month with an eligible Lilly discount card — prices move; that is access chatter, not a coupon. forum
Gray “oral GLP-1” powders: Forum capsules claiming orforglipron or generic “oral GLP-1” are not Foundayo tablets. Identity and dose accuracy stay open. forum
Branded tablet: Foundayo (orforglipron) — FDA-approved April 1, 2026 for chronic weight management with diet and activity. Once-daily swallow, any time, with or without food. trial
vs oral Wegovy / Rybelsus: Oral Wegovy is peptide semaglutide with fasting/water rules (weight). Rybelsus is the T2D oral sema. Foundayo is the no-food-rule weight pill. Do not collapse the three. trial
Injectable → oral: ATTAIN-MAINTAIN studied switch from Wegovy or Zepbound to orforglipron for maintenance — a sequenced prescription path, not gray stacking. trial

Labs people mention 4

Heart rate: Mean pulse rose ~4–5 bpm in ATTAIN-1 — class-consistent; some users track resting HR on a watch. trialforum
A1c / glucose: ACHIEVE diabetes programs and ATTAIN-1 prediabetes secondaries are why people still watch sugar even on a weight pill. trial
Lipids / waist / BP: ATTAIN-1 cardiometabolic secondaries (TG, non-HDL, systolic BP, waist) are the screenshot next to the scale. trial
Not a DIY stack lab: If someone is also on insulin or a secretagogue, hypoglycemia watch is clinician territory. trial

Storage notes 2

No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Related 10

Watch for 23

Lean mass / “Ozempic face”: Fast loss without protein + lifting linked to soft-face and strength complaints — confounded by rate of loss, not orf-unique. forum
Access / authenticity: Outside approved channels — counterfeit oral weight-loss pills, legal status by country, and purity risks. forum
Expectation honesty: Mean obesity loss is meaningful but generally below dual/triple injectable high-dose means — disappointment risk if sold as “tirz in a pill.” forum
Label hair-loss line: Foundayo common-AE lists include hair loss with the GI cluster — 2026 first-use threads notice it the same way other GLP rapid-loss logs do. trialforum
GI class effects (most common): Nausea, vomiting, diarrhea, constipation, dyspepsia, decreased appetite — mostly mild–moderate, peak at start and each titration step. trial
Phase 2 GI burden: Nausea ~37–58% across orf cohorts vs ~10% placebo; vomiting ~14–32% vs ~6%; AE discontinuation ~10–17% (mostly GI during escalation). trial
ATTAIN-1 GI rates (6 / 12 / 36 mg): Nausea ~28.9% / ~35.9% / ~33.7% vs ~10.4% placebo; constipation ~21.7% / ~29.8% / ~25.4% vs ~9.3%; diarrhea ~21.0% / ~22.8% / ~23.1% vs ~9.6%; vomiting ~13.0% / ~21.4% / ~24.0% vs ~3.5%. trial
ATTAIN-1 AE discontinuation: ~5.3% (6 mg), ~7.9% (12 mg), ~10.3% (36 mg) vs ~2.7% placebo; GI-related DC subset ~3.5–7.0% on drug vs ~0.4% placebo. trial
ACHIEVE-3 tolerability vs oral sema: Higher AE discontinuation on orf (~8.7% at 12 mg / ~9.7% at 36 mg) vs oral semaglutide (~4.5% / ~4.9%) in head-to-head T2D reporting — study not always powered as a formal safety superiority test. trial
Rapid titration penalty: Faster weekly escalation in some Phase 2 cohorts linked to more GI — slow monthly-style steps are the Phase 3/label culture. trial
Heart rate: Mean pulse rise ~4–5 bpm class-consistent in ATTAIN-1; monitor in susceptible patients per clinical practice. trial
Gallbladder / biliary: Class association with cholelithiasis/cholecystitis with rapid loss; ATTAIN-1 gallbladder-disease and cholelithiasis events occurred at low single-digit % rates. trial
Pancreatitis flag: ATTAIN-1 reported a small number of adjudication-confirmed mild pancreatitis cases in orforglipron arms; severe lasting epigastric pain is a medical red-flag class-wide. trial
Thyroid C-cell / MTC talk: The Foundayo boxed warning draws on GLP-1 receptor-dependent rodent C-cell tumors with other active agents. Orforglipron itself is not pharmacologically active in rats/mice and did not produce tumors in the label's rodent studies. Human relevance remains undetermined; personal/family MTC or MEN2 remains a Foundayo contraindication, not reassurance from negative rodent results. trial
Hypoglycemia: Low alone when not paired with insulin/secretagogues; risk rises with those combos (class glucose-dependent mechanism). trial
Dehydration / kidney stress: Persistent vomiting/diarrhea → volume depletion → AKI talk; fluids matter. trial
Gastroparesis / procedure aspiration: Delayed emptying can worsen motility issues; anesthesia/aspiration caution discussed for GLP-1 class around procedures. trial
Oral drug absorption: Delayed gastric emptying may alter absorption of some oral meds (including oral contraceptives in class labeling culture). trial
Hepatic signal: Multiple Phase 3 summaries state no hepatic safety signal identified for orforglipron — still not a free pass for unmonitored polypharmacy. trial
Pregnancy / planning: Not for pregnancy discussions; washout relative to multi-day half-life is clinician territory. trial
Not risk-free: Strong oral convenience + solid weight data still sit next to dose-dependent GI burden and class rare risks. trial
Do not combine with another GLP-1 RA: Approved-label caution; dual oral+inject full-dose talk is a GI-load thread, not a studied stack. trial
Boxed thyroid / MTC-MEN2: Same class contraindication framing as other GLP-1 RAs on the Foundayo label. trial

Updated: 2026-09-01

Evidence mix More trial/lab tags than forum tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.

↑ Back to top

Half-life & effect duration

Timing context & sources⌄

Half-life in the body

Felt duration people report

Other context in this card

What people say 20

Doses people talk about 19

How it may feel 10

Around the dose 7

Cycles people discuss 7

Timing 13

More on what it is 9

Stacks 10

Access talk 6

Labs people mention 4

Storage notes 2

Related 10

Watch for 23

Timing context & sources